American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 475-485 , September 2008

Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression

  • Fausta Catapano, MD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
    • ,
  • Paolo Chiodini, MSc

      Affiliations

    • Chair of Biostatistics at Second University of Naples, Naples, Italy
    • ,
  • Luca De Nicola, MD, PhD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
    • ,
  • Roberto Minutolo, MD, PhD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
    • ,
  • Pasquale Zamboli, MD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
    • ,
  • Ciro Gallo, MD

      Affiliations

    • Chair of Biostatistics at Second University of Naples, Naples, Italy
    • ,
  • Giuseppe Conte, MD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
    • Corresponding Author InformationAddress correspondence to Giuseppe Conte, MD, Cattedra di Nefrologia, Dip Gerontologia, Geriatria, Mal Metabolismo, Seconda Università di Napoli, Piazza Miraglia, 80138 Napoli, Italia

Received 31 October 2007 ,Accepted 3 March 2008.

References 

  1. US Renal Data System. Excerpts from the USRDS 2006 Annual Data Report (Incidence and prevalence). Am J Kidney Dis. 2007;49(suppl 1):S67–S84
  2. Sasso FC, De Nicola L, Carbonara O, et al. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:498–503
  3. Remuzzi G, Ariela Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288–296
  4. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863
  5. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic disease: Pathophysiology and indications. Kidney Int. 2005;67:799–812
  6. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908–1919
  7. Lea J, Greene T, Herbert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2005;165:947–953
  8. Levey AS, Andreoli SP, DuBose T, Provenzano R, Collins AJ. CKD: Common, harmful, and treatable. Am J Kidney Dis. 2007;49:175–179
  9. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–1219
  10. Komine N, Khang S, Wead LM, et al. Effect of combining an ACE inhibitor and an angiotensin II blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis. 2002;39:159–164
  11. Forelaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade (Is there truly a benefit of adding an ACE inhibitor?). Hypertension. 2003;41:31–36
  12. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18–25
  13. Berger ED, Bader BD, Ebert C, et al. Reduction of proteinuria; Combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens. 2002;20:739–743
  14. Ferrari P, Marti H-P, Pfister M, et al. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens. 2002;48:8–20
  15. Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant. 2002;17:597–601
  16. Kim M-J, Song JH, Suh JH, et al. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: Differential short term response between IgA nephropathy and diabetic nephropathy. Yonsei Med J. 2003;44:463–472
  17. Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 2003;63:1094–1103
  18. Song JH, Lee SW, Suh JH, et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-β excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol. 2003;60:318–326
  19. Rutkowski P, Tycliki L, Renke L, et al. Low dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis. 2004;43:260–268
  20. MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blocker and ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8–20
  21. Blecker S, Shah N. Angiotensin and renal disease: The jury is still out. Am J Kidney Dis. 2007;49:497
  22. De Nicola L, Minutolo R, Chiodini P, et al. Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney Int. 2006;69:538–545
  23. Marin R, Fernandez-Vega F, Gorostidi M, et al. Blood pressure control in patients with chronic renal insufficiency in Spain: A cross-sectional study. J Hypertens. 2006;24:395–402
  24. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials. 1996;17:1–12
  25. Douglas K, O'Maley PG, Jackson JL. Meta-analysis: The effect of statins on albuminuria. Ann Intern Med. 2006;145:117–124
  26. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45:769–773
  27. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials (I: Continuous outcomes). Stat Med. 2002;21:2131–2144
  28. Deeks JJAD, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In:  Egger MD-SG,  Altman DG editor. Systematic Reviews in Health Care. London, UK: BMJ; 2001;p. 285–312
  29. Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: Multivariate approach and meta-regression. Stat Med. 2002;21:589–624
  30. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: A comparison of methods. Stat Med. 1999;18:2693–2708
  31. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement. Lancet. 1999;354:1896–1900
  32. Kanno Y, Takenaka T, Nakamura T, et al. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney disease and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol. 2006;1:730–737
  33. Horita Y, Tadokoro M, Taura K, et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res. 2004;27:963–970
  34. Renke M, Tylicki L, Rutkowski P, et al. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. Scand J Urol Nephrol. 2004;38:427–433
  35. Segura J, Praga M, Campo C, et al. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst. 2003;4:43–47
  36. Luno J, Barrio V, Goicoechea MA, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int Suppl. 2002;82:S47–S52
  37. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial. Lancet. 2003;361:117–124
  38. Zoccali C, Valvo E, Russo D, et al. Anti-proteinuric effect of losartan in patients with chronic renal diseases. Nephrol Dial Transplant. 1997;12:234–235
  39. Russo D, Pisani A, Balletta MM, et al. Additive anti-proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33:851–856
  40. Minutolo R, Balletta MM, Catapano F, et al. Mesangial hypercellularity predicts antiproteinuric response to dual blockade of RAS in primary glomerulonephritis. Kidney Int. 2006;70:1170–1176
  41. Iodice C, Balletta MM, Minutolo R, et al. Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. Kidney Int. 2003;63:2214–2221
  42. Hebert LA, Wilmer WA, Falkenhain ME, et al. Renoprotection: One or many therapies?. Kidney Int. 2001;59:1211–1226
  43. Wilmer WA, Rovin BH, Herbert CJ, et al. Management of glomerular proteinuria: A commentary. J Am Soc Nephrol. 2003;14:3217–3232
  44. Fernandez-Juarez G, Barrio V, Garcia de Vinuesa S, et al. Dual blockade of the renin-angiotensin system in the progression of renal disease: The need for more clinical trials. Kidney Int Suppl. 2006;17:S250–S254
  45. Kincaid-Smith P, Fairley KF, Packham D. Dual blockade of the rennin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: Effects on proteinuria and blood pressure. Nephrol Dial Transplant. 2004;19:2272–2274
  46. Laverman GD, Navis G, Henning RH, et al. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020–1025
  47. Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 2006;69:1410–1415
  48. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clin Nephrol. 2003;60:1167–1172
  49. Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC North American IgA Nephropathy Study Group. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin J Am Soc Nephrol. 2006;1:1167–1172
  50. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–1140
  51. Ogden LG, Hè J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539–545
  52. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006;1:229–235
  53. Song JH, Cha SH, Hong SB, et al. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. Kidney Int Suppl. 2006;1:S101–S108
  54. Fuiano G, Mancuso D, Indolfi C, et al. Early detection of progressive renal dysfunction in patients with coronary artery disease. Kidney Int. 2005;68:2773–2780
  55. Ruilope LM, Aldigier JC, Ponticelli C, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens. 2000;18:89–95
  56. Lau J, Ioannidis JPA, Terrin N, et al. The case of the misleading funnel plot. BMJ. 2006;333:597–600
  57. Terrin N, Schmid CH, Lau J, et al. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003;22:2113–2126
  58. Schwartzer G, Artes G, Schumacher M. Inflation of type I error rate in two statistical tests for the detection of publication bias in meta-analysis with binary outcomes. Stat Med. 2002;21:2465–2477
  59. Robertson C, Idris NR, Boyle P. Beyond classical meta-analysis: Can inadequately reported studies be included?. Drug Discov Today. 2004;9:924–931
  60. Gansevoort RT, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE mediated by interference in the renin-angiotensin system?. Kidney Int. 1994;45:861–867

 Originally published online as doi:10.1053/j.ajkd.2008.03.008 on May 8, 2008.

PII: S0272-6386(08)00582-9

doi: 10.1053/j.ajkd.2008.03.008

American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 475-485 , September 2008

Article Tools

* Image Usage & Resolution